Which brand-name drugs are about to cost far more to import, and which prescriptions are left alone entirely, are both spelled out in a presidential proclamation reaching its second and final phase-in date this month. Generic medications and biosimilars are excluded outright, along with a short list of specialty drug categories that can qualify for a zero rate on a case-by-case basis. What is not excluded is patented, branded pharmaceuticals and their active ingredients, which face a 100 percent tariff on imports from any company that has not separately arranged reduced treatment with the Commerce Department.
Which Drugs Face the New 100 Percent Rate
The tariff comes from Proclamation 11020, signed April 2 and published in the Federal Register a week later, after a Commerce Department investigation under Section 232 of the Trade Expansion Act of 1962 concluded that dependence on imported pharmaceuticals threatens national security. The proclamation cites Food and Drug Administration figures showing that roughly 53 percent of patented pharmaceutical products distributed domestically are produced outside the country, with only 15 percent of patented active pharmaceutical ingredients manufactured in the United States by volume, despite the country leading the world in pharmaceutical research and development. Based on those findings, the order imposes a 100 percent ad valorem duty on imports of patented pharmaceuticals and associated active pharmaceutical ingredients named in its Annex I list, except where another provision of the same proclamation applies.
The scope is narrow by design: only patented, brand-name drugs and their ingredients are targeted, not the pharmaceutical supply chain broadly. Pharmaceutical products already made in the United States are not subject to the tariff at all, and importers can apply for duty drawback on products covered elsewhere in trade law. For an older American managing a chronic condition with a brand-name drug that has no generic substitute, the practical question is which manufacturer supplies it, and whether that company falls into the taxed group or one of the exemptions described below.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. Our free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
A Phase-In Already Underway: July 31, Then September 29
The tariff did not arrive all at once. The proclamation set two effective dates: 12:01 a.m. Eastern time on July 31, 2026, for the group of companies named in its Annex III, and September 29, 2026, for every other covered company. The first date has already passed, and the larger manufacturers on that list have been paying the 100 percent rate on covered imports since late July. The second date is the one still ahead, arriving later this month for the remaining companies that import patented pharmaceuticals and have not secured one of the reduced-rate arrangements described below. The tariff attaches to goods entered for consumption, or withdrawn from a bonded warehouse for consumption, on or after the applicable effective date, so the timing of a shipment’s customs entry, not its manufacture date, determines which rate applies.
The proclamation’s own text says the tariff is to continue in effect “unless such actions are expressly reduced, modified, or terminated,” and it directs the Commerce Secretary to publish a Federal Register notice for any change, including a rate increase for a company’s noncompliance with an onshoring or pricing commitment, or a reduction tied to a completed pharmaceutical pricing agreement with the United Kingdom. As of this writing, no such notice has altered the September 29 date for the broader group of companies.
Generics, Biosimilars and the Other Carve-Outs
The proclamation states plainly that generic pharmaceuticals and their associated ingredients, including biosimilar products, are not subject to the tariff, and that determination also covers generic purchases for the government’s Strategic API Reserve. United States-origin pharmaceutical products are excluded outright as well, regardless of a company’s size or agreements. The exemption is not written as permanent, though: within one year of the proclamation’s date, the Commerce Secretary must report to the President on any circumstances that might indicate a need to eventually adjust imports of generic pharmaceuticals and their ingredients.
A separate clause sets a zero tariff rate for several specialty categories, but only once the Commerce Secretary determines the products meet specific conditions tied to a trade and security framework agreement or an urgent domestic health need. Those categories include drugs whose approved indications are all designated orphan under the Orphan Drug Act, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, medical countermeasures for chemical, biological, radiological or nuclear threats, and animal-health products. Because that zero rate depends on a case-by-case determination rather than a blanket carve-out, a drug in one of those categories is not automatically tariff-free until the Secretary makes and publishes that finding.
Discounts for Onshoring Plans and Pricing Agreements
Companies that have, or that the Secretary assesses are likely soon to have, a Commerce-approved plan to move pharmaceutical production onshore pay a reduced 20 percent rate instead of 100 percent, though that discount is written to expire on its own: the 20 percent rate rises to 100 percent on April 2, 2030. A company that instead signs a Most-Favored-Nation pricing agreement with the Department of Health and Human Services, tying its United States prices to lower prices it charges abroad, can qualify for a zero tariff rate that runs through January 20, 2029.
Separate reduced rates apply by trade partner rather than by company. Patented pharmaceuticals from Japan, the European Union, and South Korea, along with Switzerland and Liechtenstein jointly, carry a 15 percent rate, and products of the United Kingdom carry a 10 percent rate that the proclamation says will fall to zero once a pending pharmaceutical pricing agreement between the two countries is finalized. Proclamation 11020 states that any such reduction takes effect only once the Commerce Secretary publishes it in the Federal Register, the same publication that carries the tariff structure itself.
This article was produced with the assistance of AI and reviewed by The Financial Wire editorial team.
More Financial Reading
- How many CDs can you park at 1 bank? FDIC rules you must know
- The ideal retirement withdrawal rate so your savings actually last
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
